Burry 1989.

Study characteristics
Methods	Trial design: Parallel, double‐blind, double‐dummy randomised trial
Participants	Participants: 53 women were randomised; 51 were analysed. Mean age: 23‐38 years Inclusion criteria:  Endometriosis diagnosis made laparoscopically within 3 months preceding the study Exclusion criteria:  Medical therapy for endometriosis within the preceding 6 months Setting: United States of America Timing: Not stated
Interventions	Group I: danazol, 800 mg/day (400 mg twice daily) (n = 10)  Group II: danazol, 600 mg/day (200 mg three times a day) (n = 8) Group III: intranasal nafarelin, 800 μg/day (400 μg twice a day) (n = 10) Group IV: intranasal nafarelin, 400 μg/day (200 μg two times a day) (n = 25)
Outcomes	Change in symptoms (pelvic pain and vaginal bleeding) Adverse effects Plasma lipids Stage of endometriosis  Pregnancy
Notes	Intention‐to‐treat analysis: No Sample size calculation: not stated Funding: not stated Included in this review, but did not contribute any data Not possible to contact leading author; unfortunately had passed away.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'Randomly allocated'. No further details were provided of method used to generate the randomisation sequence.
Allocation concealment (selection bias)	Unclear risk	No details were provided of method used to conceal treatment group allocation.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The study had a parallel, double‐blind, double‐dummy design.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The study had a parallel, double‐blind, double‐dummy design.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Group I: Danazol, 800 mg/day (400 mg twice a day): Nine of the 10 patients included in this group completed the study; one withdrew because of severe headaches. Group II: Danazol, 600 mg/day (200 mg three times a day). All eight patients completed the study. Group III: Nafarelin acetate, 800 μg/day (400 μg twice a day). Nine of 10 patients included in this group completed the study: one withdrew because of mood swings. Group IV: Nafarelin acetate, 400 μg/day (200 μg twice a day). All 25 patients included in this group completed the study.
Selective reporting (reporting bias)	High risk	Change in symptoms was asked for, but not reported in published article.
Other bias	Low risk	No other risk of bias detected